Skip to main content
OPTIMMUNIZE 2022

OPTIMMUNIZE 2022

In 2022 OPTIMMUNIZE organizes a conference in Odense, It will be held on November 9th-11th

Click here to register
"Early Bird" registration price: before 15 August 2022
Submission of abstracts: before 12 September 2022
Submission of late breaking abstracts: before 10 October 2022

 


We look forward to welcoming you to ‘Optimmunize 2022’ in Denmark at the Danish Institute for Advanced Study at the University of Southern Denmark from the 9th-11th of November, 2022

With best wishes from the Organising Committee, Eleanor Fish, Katie Flanagan, Sabra Klein, Tobias Kollmann, Jorge Dominguez-Andres, Frederik Schaltz-Buchholzer, Christine Stabell Benn

Our intent is to attract eminent international research scientists, policy makers, journal editors and major foundations to engage in open-minded and fulsome discussions surrounding non-specific and sex-differential effects of vaccines, and how emerging knowledge may be applied for improved public health.

Registration is now open:

https://event.sdu.dk/optimmunize2022/

As we waited for specific SAS-CoV-2  vaccines to be developed, many trials around the world were initiated to test the hypothesis that non-specific effects (NSEs) afforded by existing vaccines might be beneficial in adults, reducing the incidence and/or severity of COVID-19. . The “Pre-Optimmunize 2022” webinar will present results from such trials, conducted in many different countries, examining  whether BCG vaccine, measles-containing vaccines or oral polio vaccines should be in our pandemic toolbox.

Confirmed speakers:

  • Christine S. Benn (DK)
  • Mihai Netea (NL)
  • Evangelos Giamarellos-Bourboulis (GR)
  • Andreas Diacon (SA)
  • Anne Marie Rosendahl Madsen (DK)
  • Denise Faustman (US)
  • Edison Fedrizzi (BR)
  • Ane Fisker (DK)

 

Register here! (Free of charge)

  • Jorge Dominguez-Andres
  • Eleanor Fish
  • Katie Flanagan
  • Sabra Klein
  • Tobias Kollmann
  • Frederik Schaltz-Buchholzer
  • Christine Stabell Benn

 

More information

Confirmed speakers for the webinar

  • Mihai Netea, The Netherlands
  • Evangelos Giamarellos-Bourboulis, Great Britain
  • Andreas Diacon, South Africa
  • Denise Faustman, United States
  • Ane Fisker, Denmark
  • All members of Optimmunize

The conference will start at approximately 1 pm 9 November 2022 and close at approximately 2pm on 11 November 2022.

Topics will include:

  • Epidemiologic studies of NSEs – new studies since 2020
  • Immunologic studies of NSEs – new studies since 2020
  • Applying NSEs of vaccines against COVID-19
  • Sex-differences in immunity and response to vaccines
  • Vaccine NSEs and non-infectious diseases
  • The roles of NSEs and potential sex-differences in vaccine responses in the elderly
  • NSEs of maternal immunization
  • NSEs: policy implications, advocacy, and impact

We welcome abstracts from all areas relevant to the main themes of the meeting, for both oral and poster presentations. Several oral presentations will be chosen from the abstracts submitted.

Abstracts will only be considered from registered delegates. Please use our online abstract submission system and follow the instructions given to ensure your abstract is submitted correctly. All abstracts must be submitted by the deadline. If you are intending to submit more than one abstract, please contact the conference organiser prior to registration.

The scientific programme committee will assess your abstract after the deadline has passed and you will be notified whether you have been selected for an oral or poster presentation.

Poster boards onsite will accommodate 118 cm high by 84 cm wide (A0-portrait) of printed material. Accepted abstracts will appear in the conference programme book and poster boards will be allocated at the conference.

Deadline for submission of abstracts: 12 September 2022

Deadline for submission of late breaking abstracts: 10 October 2022

 

Abstract guidelines

Costs include registration, lunch and refreshments 9-11 November, dinner and drinks 9 November

   Early bird (until  August 2022) Standard rate (after 15 August 2022) 
Student (incl. PhD student)   1500 DKK (~200 Euro)  1500 DKK
 Academia  1500 DKK  2250 DKK (~300 Euro)
 Commercial  3000 DKK (~400 Euro)  3000 DKK (~400 Euro)

Please note that these prices are without VAT

 

Register for the conference here!

 

 



 

Optimmunize: Improving the beneficial effects of vaccines.

In 2020, just before the pandemic hit, the world’s 1st conference on non-specific and sex-differential effects of vaccines was held in Cambridge, UK: Optimmunize: Improving the beneficial effects of vaccines (read more).

We had 100 participants from around the world and our meeting was heralded as a great success: the evaluations were overwhelmingly positive; many expressed that it was the best conference they had attended in years. 

At that 2020 meeting we discussed whether vaccines exhibiting beneficial non-specific effects have a role to enhance immunity in the interim ahead of SARS-CoV-2-specific vaccine availability. Subsequently, many of us who had attended the conference initiated randomized trials to test this hypothesis; results are anticipated in the coming months. 

There have been other exciting developments in the field that emphasize the need for a follow-up conference. Accordingly, we are now planning for
Optimmunize 2022’ to take place in Denmark, at the Danish Institute for Advanced Study at the University of Southern Denmark, from  November 9-11, 2022

 

Our intent is to attract eminent international research scientists, policy makers, journal editors and major foundations to engage in open-minded and fulsome discussions surrounding non-specific and sex-differential effects of vaccines, and how emerging knowledge may be applied for improved public health. 

We will discuss and explore various aspects of the non-specific effects of vaccines, including their impact on neonates and infants, how generalisable and durable these effects are, the implications for geriatric medicine, and why non-specific effects should differ between sexes and across the lifespan. The objective is to have an open and transparent discussion of the science, while focusing on how to further optimize the use of vaccines.

We would like to encourage networking and discussion and welcome particularly young researchers to engage with speakers and fellow delegates. We invite early career scientists to prepare one critical question relevant to the meeting topics. 

  • Jorge Dominguez-Andres
  • Eleanor Fish
  • Katie Flanagan
  • Sabra Klein
  • Tobias Kollmann
  • Frederik Schaltz-Buchholzer
  • Christine Stabell Benn

Confirmed speakers for the webinar

  • Mihai Netea (NL)
  • Evangelos Giamarellos-Bourboulis (GR)
  • Andreas Diacon (SA)
  • Anne Marie Rosendahl Madsen (DK)
  • Denise Faustman (US)
  • Edison Fedrizzi (BR)
  • Ane Fisker (DK)
  • Gerald Parzmair (GER)

 

The webinar will start at 12 noon 21 April 2022 and close at approximately 4pm on 21 April 2022.

Time (CET)

Speaker

Preliminary title

12.00-12.10

Christine S. Benn (DK)

Introduction, presentation of conference in November

12.10-12.30

Mihai Netea (NL)

BCG vaccine against COVID-19 – the Dutch trials

12.30-12.50

Evangelos Giamarellos-Bourboulis (GR)

BCG vaccine against COVID-19 – the Greek trials

12.50-13.10

Andreas Diacon (SA)

BCG vaccine against COVID-19 – the South African trial

13.10-13.20

Break

 

13.20-13.40

Anne Marie Rosendahl Madsen (DK)

BCG vaccine against COVID-19 – Danish trial

13.40-14.00

Denise Faustman (US)

BCG vaccine against COVID-19 – the US trial

14.00-14.20

Edison Fedrizzi (BR)

Measles-mumps-rubella vaccine against COVID-19 – the Brazilian trial

14.20-14.40

Ane Fisker (DK)

Oral polio vaccine against COVID-19 – the Guinean trial

14.40-15.00

Gerald Parzmair (GER)

VPM1002 vaccine against COVID-19 – the German trial

15.00-16.00

Panel discussion

Moderator :  Sabra Klein (US)
Panel: Christine Stabell Benn (DK), Konstantin Chumakov (US), Nigel Curtis (AUS), Eva Kaufman (CAN)


Registration for the webinar here! (Free of charge)

 

 

Responsible for page: Danish Institute for Advanced Study

Editing was completed: 01.12.2021